CytoDyn, Inc. (OTC: CYDY)
Next Super Stock investor conference presentation 8/15/2019
CytoDyn, Inc. (OTC: CYDY) NEXT SUPER STOCK investor conference presentation
Healthcare
CytoDyn (OTC: CYDY) Receives IRB Approval To Proceed With Compassionate Use Of Leronlimab For Patients With Triple-Negative Breast Cancer
VANCOUVER, Washington, Nov. 12, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has […]
Healthcare
CytoDyn (OTC: CYDY) Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial
VANCOUVER, Washington, Dec 03, 2019 — First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 […]
Healthcare
Impressive Results Continue from CytoDyn’s (OTC: CYDY) Clinical Trials Evaluating Two Patients with Leronlimab, One in mTNBC and One in MBC
VANCOUVER, Washington, Jan 22, 2020 — First patient with metastatic triple-negative breast cancer (mTNBC) continues to show no detectable circulating tumor cells (CTC) or putative metastatic tumor cells after 15 weeks of treatment with leronlimab […]